title: Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey.
abstract: OBJECTIVE
  The treatment of choice for early or moderately advanced hepatocellular carcinoma (HCC) with good liver function remains controversial. We evaluated the therapeutic impacts of surgical resection (SR), percutaneous ethanol injection (PEI), and radiofrequency ablation (RFA) on long-term outcomes in patients with HCC.
  
  
  METHODS
  A database constructed on the basis of a Japanese nationwide survey of 28,510 patients with HCC treated by SR, PEI, or RFA between 2000 and 2005 was used to identify 12,968 patients who had no more than 3 tumors (≤ 3 cm) and liver damage of class A or B. The patients were divided into SR (n=5361), RFA (n=5548), and PEI groups (n=2059). Overall survival and time to recurrence were compared among them.
  
  
  RESULTS
  Median follow-up was 2.16 years. Overall survival at 3 and 5 years was respectively 85.3%/71.1% in the SR group, 81.0%/61.1% in the RFA, and 78.9%/56.3% in the PEI. Time to recurrence at 3 and 5 years was 43.3%/63.8%, 57.2%/71.7%, and 64.3%/76.9%, respectively. On multivariate analysis, the hazard ratio for death was significantly lower in the SR group than in the RFA (SR vs. RFA:0.84, 95% confidence interval, 0.74-0.95; p=0.006) and PEI groups (SR vs. PEI:0.75, 0.64-0.86; p=0.0001). The hazard ratios for recurrence were also lower in the SR group than in the RFA (SR vs. RFA:0.74, 0.68-0.79; p=0.0001) and PEI groups (SR vs. PEI:0.59, 0.54-0.65; p=0.0001).
  
  
  CONCLUSIONS
  Our findings suggest that surgical resection results in longer overall survival and time to recurrence than either RFA or PEIin patients with HCC [corrected].
authors.affiliation: Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Japan.
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Hasegawa
authors.forename: Norihiro
authors.initials: N
authors.lastname: Kokudo
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Makuuchi
authors.forename: Namiki
authors.initials: N
authors.lastname: Izumi
authors.forename: Takafumi
authors.initials: T
authors.lastname: Ichida
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kudo
authors.forename: Yonson
authors.initials: Y
authors.lastname: Ku
authors.forename: Michiie
authors.initials: M
authors.lastname: Sakamoto
authors.forename: Osamu
authors.initials: O
authors.lastname: Nakashima
authors.forename: Osamu
authors.initials: O
authors.lastname: Matsui
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Matsuyama
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000601:surgery* / Q000628:therapy*; D017115:Catheter Ablation; D015331:Cohort Studies; D003625:Data Collection; D016208:Databases, Factual; D000431:Ethanol / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007564:Japan; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000601:surgery* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000209:etiology; D000078702:Radiofrequency Therapy; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000431:Ethanol